A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Conditions: COVID-19; Sars-CoV2; Cancer; Solid Tumor; Carcinoma; Blood Cancer Interventions: Drug: Part 1 - TL-895; Drug: Part 2 - TL-895; Drug: Part 2 - Placebo Sponsor: Telios Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | COVID-19 | Pharmaceuticals | Research | SARS | Study